Multi-lineage progenitor cells

• US 7,622,108 B2
• Filed: 08/22/2005
• Issued: 11/24/2009
• Est. Priority Date: 04/23/2004
• Status: Active Grant

• Current Assignee: BioE LLC
• Original Assignee: BioE, Inc.
• Inventors: Sprague, Stacey L., Collins, Daniel P., Tigges, Barbara M.
• Primary Examiner(s): LEAVITT, MARIA GOMEZ
• Application Number:
  US11/208,873
• Publication Number:
  US 20060040392A1
• Time in Patent Office: 1,555 Days
• Field of Search: 424/93.1, 424/93.7, 435/2, 435/7.23, 435/7.24, 435/7.25, 435/325, 435/355, 436/523
• US Class Current: 424/93.1
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described.

Claims

1. A method of characterizing a population of multi-lineage progenitor cells (MLPC), said method comprising:

a) providing a purified population of MLPC, wherein said MLPC are positive for CD9, CD13, CD29, CD44, CD73, CD90 and CD105, and negative for CD10, CD34, CD41, CD45, Stro-1, Stage Specific Embryonic Antigen-3 (SSEA-3) and SSEA-4; and

b) assessing expression in said population of MLPC of at least one mRNA selected from the group consisting of CXCR4, FLT3, CD133, ICAM2, ITGAX, TFRC, KIT, IL6R, IL7R, ITGAM, FLT3, PDGFRB, SELE, SELL, TFRC, ITGAL, ITGB2, PECAM1, ITGA2B, ITGA3, ITGA4, ITGA6, ICAM1, CD24, CD34, CD44, CD45, CD58, CD68, CD33, CD37, CD38, TERT and POU5F.

2. The method of claim 1, wherein expression of mRNA for CXCR4, FLT3, and CD133 is assessed.

3. The method of claim 1, wherein expression of mRNA for TERT, KIT, and POU5F is assessed.

4. The method of claim 2 or 3, wherein expression of mRNA for CD34 is assessed.

5. The method of claim 1, wherein said MLPC are further negative for CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD19, CD20, CD22, CD33, CD36, CD38, CD61, CD62E, CD133, glycophorin-A, stem cell factor, and HLA-DR.

6. The method of claim 1, wherein expression of at least three mRNAs from said group is assessed.